INmune Bio (NASDAQ:INMB – Get Free Report) issued its earnings results on Thursday. Here are the key takeaways from INmune Bio’s conference call:Get INmune Bio alerts:Positive Sentiment: INmune Bio expects to submit Ebstrocel’s U.K. marketing authorization application by the end of Q3 or early Q4 2026, followed by EMA and U.S. submissions in early 2027. INmune Bio Stock PerformanceShares of INMB stock traded up $0.16 during trading hours on Friday, hitting $2.07. INmune Bio Company Profile(Get Free Report)INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. Featured StoriesReceive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.